Sign Up Today and Learn More About Neuralink Stock
Invest in or calculate the value of your shares in Neuralink or other pre-IPO companies through EquityZen's platform.
Neuralink Stock (NEUR)
Neuralink is a neurotechnology company that focuses on developing brain-computer interfaces designed to treat neurological disorders.
About Neuralink Stock
Founded
2017
Headquarters
Fremont, CA, US
Total Funding
1.3B
Industries
Hardware, Software, Science and Engineering
Neuralink is a neurotechnology company developing implantable brain-computer interfaces (BCIs). The company's technology is designed to help individuals with neurological disorders restore mobility and communication abilities. Neuralink is also developing robotic surgical systems to perform the implantation procedure with high accuracy. By advancing implantable brain devices, Neuralink seeks to restore user independence and improve lives.
Neuralink Press Mentions
Stay in the know about the latest news on Neuralink
The America Party is right out of the 'Musk playbook'
businessinsider • Jul 08, 2025
Musk’s Long Term Plans Are Really Far Out
cleantechnica • Jul 07, 2025
Neurotechnology Market Size to Surpass USD 52.86 Billion by 2034 Driven by Breakthroughs in Brain-Machine Interfaces
biospace • Jul 07, 2025
CoreNest Capital Announces Investments in 10 Frontier Companies Including Safe Superintelligence (SSI), Neuralink, Perceptive, Orbit Fab and Ottonomy
globenewswire • Jul 07, 2025
Miami surgeons implant Elon Musk's Neuralink brain chip in patient
bizjournals • Jul 07, 2025
Investors in Neuralink
Discover investors in Neuralink stock and explore their portfolio companies
Neuralink Management
Leadership team at Neuralink
CEO
Jared Birchall
Co-Founder & Co-CEO
Elon Musk
Join now and verify your accreditation status to gain access to:
- Neuralink Current Valuation
- Neuralink Stock Price
- Neuralink Management
- Available deals in Neuralink and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Neuralink Cap Table and Funding History by Share Class and Liquidity Preferences
- Neuralink Revenue and Financials
- Neuralink Highlights
- Neuralink Business Model
- Neuralink Risk Factors
- Neuralink Research Report from SACRA Research
Neuralink Key Facts
- Neuralink has reported significant growth in its valuation since its founding in 2016 and is valued at around $5 billion (as of June 2023), based on privately executed stock trades. The company was previously valued at $2 billion based on its last funding round, but after a May 2024 announcement that U.S. regulators had approved a human trial on its brain chip, many bullish investors boosted the valuation. This valuation increase may reflect strong investor confidence in the company and potential for future growth.
- Neuralink has announced significant milestones in its brain-computer interface (BCI) technology and in January 2024 the first human participant in its clinical trial received the company's brain-computer interface. The study, called PRIME, is anticipated to span six years starting with an 18-month primary phase. As of January 2025, three people have received the implant with Musk predicting that in 2025 alone around 20 to 30 patients will also receive the implant. Neuralink is also reportedly focused on improving its own software that powers these chips and one of its stated goals is to cut the recalibration time to a few minutes.
- Neuralink has signaled a strategic intent to protect its intellectual property and possibly expand into new areas of neural technology. The company hopes to achieve this by filing applications with the United States Patent and Trademark Office (USPTO) to exclusively own the names Telepathy, Telekinesis, and other names for future products. In addition to Neuralink's BCI technology, the company is also exploring a vision implant product called Blindsight, after having received a "breakthrough device designation" from the FDA for a version of its implant that could be used to restore limited vision to blind people. These trademark applications may suggest Neuralink's confidence in its future products.
- Neuralink faces regulatory concerns as the company has not received regulatory approval for the general sale of its products as of March 2025 and is still considered to be experimental. The company has also been accused of violating conflict-of-interest regulations and has thus come under scrutiny from U.S. lawmakers. The law enforcement arm of the U.S. Department of Agriculture has been investigating Neuralink for potential animal-welfare violations and the Department of Transportation is separately probing Neuralink's containment measures. Any further investigations could negatively impact the company if they lead to lawsuits and more regulatory hurdles.
- Neuralink has been criticized for its lack of transparency and specifically in its way of communicating scientific news through casual social media updates rather than traditional outlets like peer reviewed publications, public repositories or pre-prints. While it is not illegal for Neuralink to not register its clinical trials, doing so "violates fundamental ethical guidelines for biomedical research," according to an ethics professor. These ethical concerns may pose a risk to the company as it could lead to public resistance and regulatory pushback towards the technology.
- Neuralink faces competition from other companies and research institutions working on similar brain-machine interface technologies. One of its main rivals is US-based Synchron which is, as of August 2024, further along in the clinical trial process than Neuralink and is preparing to recruit patients for a large-scale clinical trial ahead of commercial approval. Other competitors include BrainGate and Clinatec. There are also big tech players like Google or Meta that could enter the brain-computer interface market.
Trading Neuralink Stock
How to invest in Neuralink stock?
Accredited investors can buy pre-IPO stock in companies like Neuralink through EquityZen funds. These investments are made available by existing Neuralink shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Neuralink stock?
Shareholders can sell their Neuralink stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
